SUPERIOR APPROACH IMPLANTATION OF ENDOCARDIAL LV LEAD IS EFFECTIVE IN PROVIDING CARDIAC RESYNCHRONIZATION THERAPY

years), respectively, and had a lower prevalence of comorbid conditions (Table). Except for beta-blocker use, women were less likely to be prescribed cardiac medications such as ACE inhibitors and anti-arrhythmics. The KM survival estimates were 0.95 at 1-year for both sexes, 0.79 for women and 0.73 for men at 5 years, and 0.70 for women and 0.57 for men at 8 years; the overall survival of women was greater than men (Figure). After adjusting for age, diabetes, coronary artery disease, congestive cardiomyopathy, peripheral vascular disease, acquired heart surgery, and anti-arrhythmic drug use, in the Cox proportional-hazards model, the sex difference in mortality was attenuated and no longer significant, adjusted HR 0.91, (95% CI: 0.75,1.12). CONCLUSION: Mortality trends from our population reveal that there is no difference in survival between women and men with ICDs. This may imply that women with ICDs derive the same benefit as men. Ongoing analyses will determine whether the impact of sex on mortality is different among patients receiving an ICD for primary versus secondary prevention and among those with ICDs compared to a similar population without ICDs. 536 SUPERIOR APPROACH IMPLANTATION OF ENDOCARDIAL LV LEAD IS EFFECTIVE IN PROVIDING CARDIAC RESYNCHRONIZATION THERAPY